Anti-HER2 (Trastuzumab biosimilar - IgA2 isotype)

Product Unit size Cat. code Docs. Qty. Price


HER2 (Trastuzumab) antibody - Human IgA2

Show product

100 µg

3 x 100 µg

  • About
  • Specifications
  • Contents

Monoclonal human IgA2 antibody against HER2

Effector functions of mAb isotypes targeting CD20

Anti-HER2-Tra-hIgA2 features the constant region of the human IgA2 isotype and the variable region of trastuzumab. Trastuzumab is a humanized IgG1 monoclonal antibody that targets the HER2 receptor (human epidermal growth factor receptor 2 also known as HER2/neu) that is found on the cell membrane of epithelial cells.

HER2 plays an important role in normal cell growth and differentiation [1]. However, in certain types of cancers, particularly in breast and ovarian cancers, HER2 is over-expressed and causes uncontrollable cell proliferation. Binding of trastuzumab to HER2 results in cell death through different mechanisms including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2, 3]. Trastuzumab has been approved by the FDA for the treatment of breast cancer.

Anti-HER2-Tra-hIgA2 was generated by recombinant DNA technology. It has been produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with peptide M



1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell- mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.


HER cell surface staining
HER cell surface staining

Binding of Anti-HER2-hIgA2 mAb to HER2. EL4 cells overexpressing HER2 were incubated for 30 minutes at 4°C with 125 ng of Anti-HER2-hIgA2 or an isotype control. Subsequently, a secondary PE-labeled antibody was added and incubated at 4°C for 30 minutes. The binding affinity was assessed using flow cytometry.

Back to the top


Specificity: Targets cells expressing HER2

Clonality: Monoclonal antibody

Clone: Trastuzumab (Anti-HER2-hIgG1, kappa)

Isotype: Human IgA2, kappa

Control: Human IgA2

Source: CHO cells

Formulation: 0.2 µm filtered solution in TRIS buffer with glycine, saccharose, and stabilizing agents

Purity: Purified by affinity chromatography with peptide M

Tested application: Flow cytometry

Quality control:

  • Binding of Anti-HER2-Tra-hIgG1 to HER2 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top


Anti-HER2-Tra-hIgA2 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • her2tra-mab7: 100 µg
  • her2tra-mab7-03: 3 x 100 µg

room temperature Product is shipped at room temperature

store Upon receipt, store at -20°C.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty